Madrigal Pharmaceuticals (MDGL) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to -$1.1 billion.
- Madrigal Pharmaceuticals' Enterprise Value fell 1112.75% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 1112.75%. This contributed to the annual value of -$926.3 million for FY2024, which is 4606.62% down from last year.
- Per Madrigal Pharmaceuticals' latest filing, its Enterprise Value stood at -$1.1 billion for Q3 2025, which was down 1112.75% from -$797.0 million recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' Enterprise Value ranged from a high of -$153.2 million in Q3 2022 and a low of -$1.1 billion during Q3 2025
- Over the past 5 years, Madrigal Pharmaceuticals' median Enterprise Value value was -$329.5 million (recorded in 2023), while the average stood at -$549.0 million.
- In the last 5 years, Madrigal Pharmaceuticals' Enterprise Value skyrocketed by 4878.99% in 2022 and then tumbled by 32979.24% in 2024.
- Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Enterprise Value stood at -$270.3 million in 2021, then tumbled by 32.71% to -$358.8 million in 2022, then tumbled by 76.75% to -$634.1 million in 2023, then plummeted by 46.07% to -$926.3 million in 2024, then fell by 19.81% to -$1.1 billion in 2025.
- Its Enterprise Value stands at -$1.1 billion for Q3 2025, versus -$797.0 million for Q2 2025 and -$843.1 million for Q1 2025.